Literature DB >> 22192142

Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma.

Di-Cing Wei1, Yi-Chen Yeh, Jung-Jyh Hung, Teh-Ying Chou, Yu-Chung Wu, Pei-Jung Lu, Hui-Chuan Cheng, Yu-Lin Hsu, Yu-Lun Kuo, Kuan-Yu Chen, Jin-Mei Lai.   

Abstract

Tumor recurrence is the most common cause of disease failure after surgical resection in early-stage lung adenocarcinoma. Identification of clinically relevant prognostic markers could help to predict patients with high risk of disease recurrence. A meta-analysis of available lung adenocarcinoma microarray datasets revealed that T-LAK cell-originated protein kinase (TOPK), a serine/threonine protein kinase, is overexpressed in lung cancer. Using stable cell lines with overexpression or knockdown of TOPK, we have shown that TOPK can promote cell migration, invasion, and clonogenic activity in lung cancer cells, suggesting its crucial role in lung tumorigenesis. To evaluate the prognostic value of TOPK expression in resected stage I lung adenocarcinoma, a retrospective analysis of 203 patients diagnosed with pathological stage I lung adenocarcinoma was carried out to examine the expression of TOPK by immunohistochemistry (IHC). The prognostic significance of TOPK overexpression was examined. Overexpression of TOPK (IHC score >3) was detected in 67.0% of patients, and these patients were more frequently characterized with disease recurrence and angiolymphatic invasion. Using multivariate analysis, patient age (>65 years old; P = 0.002) and TOPK overexpression (IHC score >3; P < 0.001) significantly predicted a shortened overall survival. Moreover, TOPK overexpression (IHC score >3; P = 0.005) also significantly predicted a reduced time to recurrence in the patients. Our results indicate that overexpression of TOPK could predetermine the metastatic capability of tumors and could serve as a significant prognostic predictor of shortened overall survival and time to recurrence.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22192142     DOI: 10.1111/j.1349-7006.2011.02197.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  19 in total

1.  CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity.

Authors:  Seth Stauffer; Yongji Zeng; Jiuli Zhou; Xingcheng Chen; Yuanhong Chen; Jixin Dong
Journal:  Cell Signal       Date:  2017-08-03       Impact factor: 4.315

2.  Expression of PBK/TOPK in cervical cancer and cervical intraepithelial neoplasia.

Authors:  Qiong Luo; Bin Lei; Shuguang Liu; Yaowen Chen; Wenjie Sheng; Peixin Lin; Wenxia Li; Haili Zhu; Hong Shen
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 3.  The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Authors:  Lu Zhang; Fei Wang; Huijun Yi; Svetlana P Ermakova; Olesya S Malyarenko; Jianmei Mo; Yingze Huang; Qiuhong Duan; Juanjuan Xiao; Feng Zhu
Journal:  Mol Cell Biochem       Date:  2022-01-17       Impact factor: 3.396

4.  TOPK Activation Exerts Protective Effects on Cisplatin-induced Acute Kidney Injury.

Authors:  Hui Zhang; Qing-Qing Dong; Hua-Pan Shu; Yu-Chi Tu; Qian-Qian Liao; Li-Jun Yao
Journal:  Curr Med Sci       Date:  2022-06-09

5.  Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.

Authors:  Mrinal Joel; Awais A Mughal; Zanina Grieg; Wayne Murrell; Sheryl Palmero; Birthe Mikkelsen; Hege B Fjerdingstad; Cecilie J Sandberg; Jinan Behnan; Joel C Glover; Iver A Langmoen; Biljana Stangeland
Journal:  Mol Cancer       Date:  2015-06-17       Impact factor: 27.401

6.  TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.

Authors:  Huimin Sun; Lei Zhang; Changhong Shi; Peizhen Hu; Wei Yan; Zhe Wang; Qiuhong Duan; Fan Lu; Lipeng Qin; Tao Lu; Juanjuan Xiao; Yingmei Wang; Feng Zhu; Chen Shao
Journal:  Oncotarget       Date:  2015-05-20

7.  Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.

Authors:  Moloy T Goswami; Guoan Chen; Balabhadrapatruni V S K Chakravarthi; Satya S Pathi; Sharath K Anand; Shannon L Carskadon; Thomas J Giordano; Arul M Chinnaiyan; Dafydd G Thomas; Nallasivam Palanisamy; David G Beer; Sooryanarayana Varambally
Journal:  Oncotarget       Date:  2015-09-15

8.  Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon.

Authors:  Juanjuan Xiao; Qiuhong Duan; Zhe Wang; Wei Yan; Huimin Sun; Peipei Xue; Xiaoming Fan; Xiaoyu Zeng; Juan Chen; Chen Shao; Feng Zhu
Journal:  Oncotarget       Date:  2016-04-26

9.  Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase.

Authors:  Jianjun Yang; Donghong Yuan; Tongchao Xing; Hongli Su; Shengjun Zhang; Jiansheng Wen; Qiqiang Bai; Dongmei Dang
Journal:  J Ginseng Res       Date:  2016-04-05       Impact factor: 6.060

Review 10.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.